Communiqués Lexeo Therapeutics, Inc.

Actions

LXEO

US52886X1072

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 20/08/2026			Varia. 5j.	Varia. 1 janv.
5,060 ^USD	-5,77%		+2,02%	-49,04%

12/08	Lexeo Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
05/08	Lexeo Therapeutics reçoit la désignation RMAT de la FDA pour le LX2020 dans le traitement de la cardiomyopathie arythmogène liée au gène PKP2	CI

Communiqués

12/08	Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights	AQ
05/08	Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy	AQ
17/06	Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia	AQ
15/06	Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia	AQ
19/05	Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	AQ
11/05	Lexeo Therapeutics : Corporate PresentationvMay2026	PU
11/05	Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights	AQ
27/04	Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting	AQ
30/03	Lexeo Therapeutics : Corporate Presentation March 2026	PU
30/03	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	AQ
03/03	Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference	AQ
05/02	Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February	AQ
27/01	Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics	AQ
12/01	Lexeo Therapeutics : JAN12 2026 LX2020 Interim Clinical Data vF	PU
12/01	Lexeo Therapeutics : Corporate Presentation J.P. Morgan Healthcare Conference January 2026	PU
12/01	Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy	AQ
08/01	Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy	AQ
22/12	Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
04/12	Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum	AQ
06/11	Lexeo Therapeutics : Corporate Presentation November 2025	PU
05/11	Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights	AQ
20/10/25	Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering	AQ
17/10/25	Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement	AQ
16/10/25	Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants	AQ
07/10/25	Lexeo Therapeutics : Corporate Presentation October 2025	PU